Recent Updates — VKTX

Viking Therapeutics reported a third-quarter 2026 net loss of $183.2 million, or $1.55 per share, compared to a $90.8 million loss in the prior-year period. The widening deficit was driven by research and development expenses rising to $166.8 million from $90.0 million, alongside general and administrative costs increasing to $20.3 million from $8.6 million. The company also announced the successful closing of concurrent upsized public offerings of common stock and convertible senior notes in September, generating approximately $575 million in gross proceeds. This financing brought quarter-end cash, cash equivalents, and short-term investments to a strong balance of $960 million. Clinically, Viking initiated the SUNRISE Phase 3 trials for its oral VK2735 formulation and reported positive maintenance dosing results from Part 1 of its range-finding study. The company operates as a clinical-stage biopharmaceutical firm focused on developing novel therapies for metabolic and endocrine disorders.

Viking Therapeutics, Inc. completed a combined equity and debt offering on September 25, 2026, raising approximately $547.8 million in net proceeds. The company issued 9,035,714 shares of common stock at $35.00 per share, generating roughly $297.0 million after underwriting discounts and the full exercise of the over-allotment option. Simultaneously, it sold $258,750,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2032, yielding approximately $250.8 million in net proceeds. The convertible notes carry an initial conversion price of roughly $50.75 per share and mature on October 15, 2032. Proceeds will fund the clinical development of VK2735 and VK3019 programs, along with general corporate purposes. Viking Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

Viking Therapeutics announced positive top-line results from the VK2735-102 maintenance study of its dual GLP-1/GIP agonist VK2735. Participants transitioned to every-other-week dosing maintained up to 97% of weight loss, while monthly dosing maintained up to 90%, compared with 61% for placebo. The exploratory weekly cohort achieved approximately 22% placebo-adjusted weight loss at Week 33 without plateau. GI adverse event rates during maintenance were comparable to placebo. Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for obesity and metabolic disorders.

Viking Therapeutics reported a net loss of $128.0 million, or $1.10 per share, for the second quarter ended June 30, 2026, compared to a net loss of $65.6 million in the prior year period. Research and development expenses increased to $115.8 million from $60.2 million due to clinical studies and salaries. The company holds $502 million in cash and short-term investments as of June 30, 2026. Clinically, Phase 3 VANQUISH trials for subcutaneous VK2735 are fully enrolled, with oral VK2735 Phase 3 initiation expected in the fourth quarter of 2026. Maintenance dosing data is anticipated in the third quarter of 2026, and a Phase 1 study for amylin agonist VK3019 has commenced. Viking appointed Hubert Chen as chief medical officer and Dorothy Gemmell to its board of directors. Viking Therapeutics operates in the biotechnology industry, developing therapies for obesity and metabolic disorders.